Metabolic profile of people living with HIV in a treatment hub in Manila, Philippines: A Pre- and Post-Antiretroviral analysis
https://doi.org/10.15605/jafes.037.01.17
- Author:
Christian Francisco
1
,
2
;
Eddieson Gonzales
3
;
Marc Gregory Yu
4
;
Edsel Maurice Salvaña
1
,
2
;
Cybele Abad
2
;
Paul Ferdinand Reganit
3
;
Patricia Maningat
4
;
Olivia Sison
5
;
Marissa Alejandria
2
,
5
Author Information
1. Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the Philippines Manila
2. Division of Infectious Diseases, Department of Medicine, University of the Philippines-Philippine General Hospital
3. Division of Cardiovascular Medicine, Department of Medicine, University of the Philippines-Philippine General Hospital
4. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of the Philippines-Philippine General Hospital
5. Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila
- Publication Type:Journal Article
- Keywords:
Antiretroviral therapy
- MeSH:
HIV;
Acquired Immunodeficiency Syndrome;
Dyslipidemias;
Hyperglycemia
- From:
Journal of the ASEAN Federation of Endocrine Societies
2022;37(1):53-61
- CountryPhilippines
- Language:English
-
Abstract:
Objectives:People living with HIV (PLHIV) are susceptible to develop dyslipidemia and hyperglycemia. This study aims to determine the prevalence of these metabolic derangements among Filipino PLHIV.
Methodology:We reviewed 635 medical records in a treatment hub in Manila, Philippines from January 2004 to July 2016. Logistic regression analysis was done to determine factors associated with dyslipidemia and hyperglycemia pre- and post-ART.
Results:Among 635 PLHIV, 97.3% were males with mean age of 30 years and median CD4 count of 207 cells/mm3. Pre-ART, prevalence of dyslipidemia was 65.4% and hyperglycemia was 10.4%. Risk factors for dyslipidemia include hyperglycemia (AOR 3.8, p 0.001) and >320 days delay in ART initiation from HIV confirmation (AOR 1.5, p 0.032), while dyslipidemia was associated with hyperglycemia (AOR 3.1, p 0.001). Post-ART, prevalence of dyslipidemia was 48.6% and hyperglycemia was 15.6%. Risk factors for post-ART dyslipidemia include being WHO stage 4 (AOR 2.1, p 0.021), hyperglycemia (AOR 16.1, p<0.001), >36 months ART duration (AOR 8.7, p<0.001) and efavirenz-based ART (AOR 2.8, p<0.001). Low CD4 count post-ART had a negative correlation with dyslipidemia (AOR 0.5, p 0.005). Post-ART hyperglycemia was associated with age >30 years (AOR 2.1, p 0.004), being overweight (AOR 1.8, p 0.023), dyslipidemia (AOR 17.8, p<0.001) and zidovudine-based ART (AOR 1.4, p 0.051).
Conclusion:Dyslipidemia and hyperglycemia prevalence was high in Filipino PLHIV. Traditional, HIV and treatment related factors contributed to its development. Intensive monitoring and initiation of appropriate treatment is recommended.
- Full text:1183-Article Text-17227-2-10-20220529 (1).pdf
